Precision BioSciences Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
69
- Stock Symbol
-
DTIL
- Share Price
-
$7.57
- (As of Friday Closing)
Precision BioSciences General Information
Description
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
Contact Information
Website
www.precisionbiosciences.comCorporate Office
- 302 East Pettigrew Street
- Durham, NC 27701
- United States
Corporate Office
- 302 East Pettigrew Street
- Durham, NC 27701
- United States
Precision BioSciences Timeline
Precision BioSciences Stock Performance
As of 13-Nov-2026, Precision BioSciences’s stock price is $7.57. Its current market cap is $289M with 38.2M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $7.57 | $8.04 | $3.53 - $11.29 | $289M | 38.2M | 319K | -$1.20 |
Precision BioSciences Financials Summary
As of 30-Sep-2026, Precision BioSciences has a trailing 12-month revenue of $45M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 113,338 | 84,396 | (41,668) | (53,872) |
| Revenue | 45,042 | 34,264 | 68,696 | 48,727 |
| EBITDA | (39,260) | (46,673) | 6,763 | (39,728) |
| Net Income | (38,546) | (45,724) | 7,167 | (61,319) |
| Total Assets | 120,376 | 154,416 | 136,388 | 159,781 |
| Total Debt | 27,720 | 28,808 | 30,045 | 31,268 |
Precision BioSciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Precision BioSciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Precision BioSciences Comparisons
Industry
Financing
Details
Precision BioSciences Competitors (59)
One of Precision BioSciences’s 59 competitors is Intellia Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Editas Medicine | Formerly VC-backed | Cambridge, MA | ||||
| Caribou Biosciences | Formerly VC-backed | Berkeley, CA | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland | ||||
| Beam Therapeutics | Formerly VC-backed | Cambridge, MA |
Precision BioSciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Precision BioSciences Patents
Precision BioSciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026234600-A1 | Engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome | Pending | 07-May-2025 | ||
| WO-2026083328-A1 | Base editing nucleotide sequences using homology directed repair | Pending | 18-Oct-2024 | ||
| WO-2026083329-A1 | Methods of nuclease-initiated homology directed repair and replacement and compositions and uses thereof | Pending | 18-Oct-2024 | ||
| WO-2026078579-A1 | Methods and compositions for treating hepatitis b virus-related conditions | Pending | 08-Oct-2024 | ||
| WO-2026028165-A1 | Engineered meganucleases having specificity for recognition sequences in the c9orf72 gene | Pending | 01-Aug-2024 | A61P25/28 |
Precision BioSciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Precision BioSciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Precision BioSciences ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
31.52 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Precision BioSciences FAQs
-
When was Precision BioSciences founded?
Precision BioSciences was founded in 2006.
-
Where is Precision BioSciences headquartered?
Precision BioSciences is headquartered in Durham, NC.
-
What is the size of Precision BioSciences?
Precision BioSciences has 69 total employees.
-
What industry is Precision BioSciences in?
Precision BioSciences’s primary industry is Drug Discovery.
-
Is Precision BioSciences a private or public company?
Precision BioSciences is a Public company.
-
What is Precision BioSciences’s stock symbol?
The ticker symbol for Precision BioSciences is DTIL.
-
What is the current stock price of Precision BioSciences?
As of 13-Nov-2026 the stock price of Precision BioSciences is $7.57.
-
What is the current market cap of Precision BioSciences?
The current market capitalization of Precision BioSciences is $289M.
-
What is Precision BioSciences’s current revenue?
The trailing twelve month revenue for Precision BioSciences is $45M.
-
Who are Precision BioSciences’s competitors?
Intellia Therapeutics, Editas Medicine, Caribou Biosciences, CRISPR Therapeutics, and Beam Therapeutics are some of the 59 competitors of Precision BioSciences.
-
What is Precision BioSciences’s annual earnings per share (EPS)?
Precision BioSciences’s EPS for 12 months was -$1.20.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
